Logo for Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Investor Relations Material

Latest events

Logo for Anebulo Pharmaceuticals

Q1 2025

13 Nov, 2024
Logo for Anebulo Pharmaceuticals

Q4 2024

25 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Anebulo Pharmaceuticals Inc

Access all reports
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for acute cannabinoid intoxication (ACI) and substance abuse. Its primary product candidate, ANEB-001, is a cannabinoid receptor antagonist aimed at rapidly reversing the effects of cannabinoid overdose. The company is headquartered in Lakeway, Texas, and its shares are listed on the Nasdaq.